Stocks · News reference

Arcutis Biotherapeutics shares are trading lower. The company announced its subsidiary Arcutis Canada secured Health Canada approval for roflumilast cream in pediatric atopic dermatitis patients.

Aug 20, 2026, 5:49 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 5:47 PMBenzinga Newsdesk
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Health Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for young children,
Read original at benzinga
ARQT
BenzingaAug 6, 2026, 5:19 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
Read original at benzinga
ARQT
BenzingaAug 6, 2026, 1:28 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Read original at benzinga
ARQT